Aktienanalyse zu Cybin Inc (HELP)HELPCybin Inc

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. It operates in the Healthcare sector.

Cybin Inc (HELP) is currently priced at $12.18, which is below the analyst price target range of $16 to $62, indicating potential upside. However, the RSI is at 45.42, suggesting the stock is neither overbought nor oversold, indicating a neutral momentum. The company has reported significant losses, with a net income of -46,995,000 CAD in the last quarter, which raises concerns about financial stability. Given these factors, it may be wise to hold off on buying until more positive indicators emerge.